

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Temporary Member's Name: Dr. James Hildreth

Committee: Vaccines and Related Products Advisory Committee (VRBPAC)

Meeting Date: February 15, 2022

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the meeting topic: The Committee will meet in open session to discuss a request to amend the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 mRNA vaccine for administration of their COVID-19 mRNA vaccine to children 6 months through 4 years of age, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	<u>Nature</u>	<u>Magnitude</u>	
I. Personal/Immediate Family			
Clinical Trial Participation	Affected Firm	\$0 - \$5,000	
II. Other Imputed Interests			
Vaccine Test Site; Meharry Medical College	(b) (4) and NIH/NIAID, Affected Firms	\$1,500,000 - \$2,000,000	
Vaccine Test Site; Meharry Medical College	(b) (4) Affected Firm	\$400,000 - \$600,000	

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/ S /	Feb 7, 2022
Signature	Date

James Hildreth, M.D., Ph.D.